# A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Source: https://onco.cc/trials/nct05262400/  
OnCo record `nct05262400` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Atirmociclib and Fulvestrant in advanced solid tumours, run by Pfizer, active and no longer recruiting.

## Summary

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors is a phase 1/2 interventional study registered as NCT05262400 by Pfizer, with 235 participants enrolled, started 2022-03-14 and due to reach its primary completion in 2027-02-26. Interventions recorded: PF-07220060 + PF-07104091 combination dose escalation, PF-07104091 + PF-07220060 + fulvestrant dose expansion and PF-07104091 + PF-07220060 + letrozole dose expansion.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05262400
- Phase: 1/2
- Setting: A PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMBINATION WITH PF-07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
- Sponsor: Pfizer
- Enrolled: 235

## Sources

- ClinicalTrials.gov NCT05262400: https://clinicaltrials.gov/study/NCT05262400

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Atirmociclib](https://onco.cc/drugs/atirmociclib/), [Fulvestrant](https://onco.cc/drugs/fulvestrant/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct05262400.json